Figueredo PYE, Luna CCM, Wilford de LM, Campos ML, Alfonso BM

Language: Spanish
References: 13
Page:
PDF size: 388.71 Kb.

ABSTRACT

The monoclonal gammapathies constitutes a group of disorders that are characterized by the abnormal proliferation of a clown of plasmatic cells, that are capable of producing monoclonal paraprotein. The Multiple Myeloma is the prototype of malignant monoclonal gammapathy .His annual frecuency is 4 cases for every 100.000 habitants. In a study of 40 patients realized in the Medical Surgical Search Center, a monoclonal band was detected by the system Hydrasys, the majority of them of novo. The most frequent immunoglobulin in this subgroup is an immunoglobulin (Ig) G, though slightly minor of what it describes Kyle for Monoclonal Gammopathy of Undetermined Significance. As for the Multiple Myeloma in the distribution according to the type of Immunoglobulin we do not find any IgM's case, but yes two of IgD which according to the information of the literature is infrequent enough. We present a patient to which there realized the diagnosis of the Multiple Myeloma IgD, dealing the same one with athipical evolution form.

REFERENCES

1. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54.

2. Alexanian R, Dimopoulos M: The treatment of multiple myeloma. N.Eng.J.Med. 1994;330(7):484-9.

3. Bizzaro N, Passini P. Familial occurrence of multiple myeloma and monoclonal gammopathy of undetermined significance in siblings. Haematologica. 1990 Jan-Feb; 75(1):58-63.

4. Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract.Res.Clin.Haematol. 2007;20:637-64.

5. Malpas JS, Bergsagel DE, Kyle RA, eds. Myeloma: Biology and Management. 2 e. Oxford, England: Oxford University Press; 1998.

6. Repiso M, Vélez de Mendizábal E, Elizondo MJ. Mieloma múltiple IgA a propósito de un caso. MEDIFAM 2002;12(2):144-148.

7. Crawford J, Eye MJ, Cohen MJ. Evaluation of monoclonal gammopathy in the well ederly. Am.J.Med. 1987;82:39-45.

8. Alexanian R, Webwe D, Liu F. Differential diagnosis of monoclonal gammopathies. Arch.Pathol.Lab.Med. 1999;123:108-13.

9. Blade J, Kyle R, Greipp P. Multiple myeloma in patients younger than 30 years. Report of 10 cases and review of the literature. Arch.Intern.Med. 1997 feb 10;157(3):361.

10. Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract.Res.Clin.Haematol. 2007;20:637-64.

11. Conte G, Figueroa G, Lois V, Cabrera M, León A, García H, et al. Mieloma múltipleen Chile. Características clínicas y sobrevida. Rev.Med.Chile. 2007;135:1111-7

12. Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungoli Gargantini L, et al. Prognostics factors for malignant transformation in monoclonal gammopath of undetermined significance and smoldering multiple myeloma. J.Clin.Oncol. 2002 Mar 15;20(6):1625-34.

13. Decaux O, Cazalets-Lacoste C, Cador-Rousseau B, Laurat E, Sebillot Bracq J, Leblay R, et al. Follow-up of monoclonal gammapathy of undetermined significance in a population of Si patients older than 70 years. Rev.Med.Int. 2002 Sep;23 (9):75 1-8.